Allogeneic stem cell transplantation
Allogeneic stem cell transplantation is an intervention with 34 clinical trials. Currently 6 active trials ongoing. Historical success rate of 83.3%.
Success Metrics
Based on 15 completed trials
Phase Distribution
Phase Distribution
12
Early Stage
14
Mid Stage
5
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
65.2%
15 of 23 finished
34.8%
8 ended early
6
trials recruiting
34
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
Clinical Trials (34)
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability
Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL
5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)
Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
Cohort Study Assessing the Treatment Strategy for High-Risk Myelodysplastic Syndromes in Patients Under 70
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 34